Policy Watch: 20 Regulatory Updates — June 21, 2026
Policy WatchJune 21, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Policy Watch: 20 Regulatory Updates — June 19, 2026
Policy WatchJune 19, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I
The DEA scheduling benzodiazepine analogs in Schedule I addresses the abuse potential of synthetic benzodiazepines. These substances pose significant clinical risks and regulatory challenges. Clinicians should be vigilant for exposure to these…
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Tennessee lawmakers split as DOJ shift reignites push for medical marijuana rules
Tennessee's medical cannabis program provides limited patient access through strict regulatory requirements and qualifying conditions. Understanding the state's framework helps patients navigate the complex process of obtaining medical cannabis…
Tennessee lawmakers split as DOJ shift reignites push for medical marijuana rules
Tennessee medical marijuana legislation updates continue to evolve, creating uncertainty for patients seeking evidence-based cannabis treatments. Current state restrictions limit access to comprehensive medical cannabis therapy despite growing clinical…
Marijuana Advocacy Groups Meet State Officials After Reclassification
State cannabis reclassification impact is reshaping patient access and regulatory frameworks. Advocacy groups meet with officials to influence policy changes. These developments affect clinical practice and patient care.